X4 Pharmaceuticals Inc • XFOR

Capital at risk.

About X4 Pharmaceuticals Inc
Ticker
info
XFOR
Trading on
info
NASDAQ
ISIN
info
US98420X2027
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
-
Headquarters
info
61 North Beacon Street, Boston, MA, United States, 02134
Employees
info
45
Website
info
x4pharma.com
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
Metrics
BasicAdvanced
Market cap
info
$347M
P/E ratio
info
2.45
EPS
info
$1.43
Dividend Yield
info
0.00%
Beta
info
0.4
Forward P/E ratio
info
0
EBIDTA
info
$-79M
Ex dividend date
info
-
Price & volume
Market cap
info
$347M
Average daily volume
info
0.8M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
2.45
Forward P/E
info
0
PEG ratio
info
-
Trailing P/E
info
2.45
Price to sales
info
21.9
Price to book
info
2.23
Earnings
EPS
info
$1.43
EPS estimate (current quarter)
info
-$0.18
EPS estimate (next quarter)
info
-$0.19
EBITDA
info
$-79M
Revenues (TTM)
info
$15.8M
Revenues per share (TTM)
info
$0.16
Technicals
Beta
info
0.4
52-week High
info
$4.83
52-week Low
info
$2.80
50-day moving average
info
$4.02
200-day moving average
info
$3.94
Short ratio
info
10.69
Short %
info
7.27%
Management effectiveness
ROE (TTM)
info
-113.08%
ROA (TTM)
info
-28.15%
Profit margin
info
0.00%
Gross profit margin
info
$12.9M
Operating margin
info
-186.13%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
346.30%
Share stats
Outstanding Shares
info
99.1M
Float
info
62.8M
Insiders %
info
0.44%
Institutions %
info
100.14%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 5 analysts.

Average price target

info
$11.60
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.69
-$0.79
12.66%
Q3 • 25Beat
-$0.22
-$0.35
36.69%
Q4 • 25Beat
-$0.16
-$0.20
20.00%
Q1 • 26Beat
-$0.13
-$0.19
31.58%
Q2 • 26Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$2.7M
$-20.2M
-747.45%
Q1 • 26
$8.8M
$-16.2M
-183.48%
Q2 • 26
225.18%
-20.18%
-75.45%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$270M
$102M
37.68%
Q1 • 26
$253M
$97.6M
38.57%
Q2 • 26
-6.37%
-4.15%
2.38%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-19.6M
$19.3M
$0M
$-19.6M
Q1 • 26
$-20.8M
$4M
$0.1M
$-40.4M
Q2 • 26
6.07%
-79.22%
3,650.00%
106.07%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a X4 Pharmaceuticals Inc share?
Collapse

X4 Pharmaceuticals Inc shares are currently traded for undefined per share.

How many shares does X4 Pharmaceuticals Inc have?
Collapse

X4 Pharmaceuticals Inc currently has 99.1M shares.

Does X4 Pharmaceuticals Inc pay dividends?
Collapse

No, X4 Pharmaceuticals Inc doesn't pay dividends.

What is X4 Pharmaceuticals Inc 52 week high?
Collapse

X4 Pharmaceuticals Inc 52 week high is $4.83.

What is X4 Pharmaceuticals Inc 52 week low?
Collapse

X4 Pharmaceuticals Inc 52 week low is $2.80.

What is the 200-day moving average of X4 Pharmaceuticals Inc?
Collapse

X4 Pharmaceuticals Inc 200-day moving average is $3.94.

Who is X4 Pharmaceuticals Inc CEO?
Collapse

The CEO of X4 Pharmaceuticals Inc is -.

How many employees X4 Pharmaceuticals Inc has?
Collapse

X4 Pharmaceuticals Inc has 45 employees.

What is the market cap of X4 Pharmaceuticals Inc?
Collapse

The market cap of X4 Pharmaceuticals Inc is $347M.

What is the P/E of X4 Pharmaceuticals Inc?
Collapse

The current P/E of X4 Pharmaceuticals Inc is 2.45.

What is the EPS of X4 Pharmaceuticals Inc?
Collapse

The EPS of X4 Pharmaceuticals Inc is $1.43.

What is the PEG Ratio of X4 Pharmaceuticals Inc?
Collapse

The PEG Ratio of X4 Pharmaceuticals Inc is null.

What do analysts say about X4 Pharmaceuticals Inc?
Collapse

According to the analysts X4 Pharmaceuticals Inc is considered a buy.